logo-loader
viewImmuPharma PLC

Update on Nucant Cancer Programme

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:72.0pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h2{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;text-align:center;text-autospace:none;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;text-decoration:underline;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .bs{size:595.3pt 841.9pt;margin:72.0pt 46.3pt 53.95pt 90.0pt;}div.bs{}p.cy{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold}span.cw{font-family:"Calibri","sans-serif"; color:black}p.cz{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-weight: bold; text-align: center}span.cu{font-family:"Calibri","sans-serif";color:black}p.da{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; text-align: center}p.db{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";background:white}p.dc{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify;background:white}span.cp{font-family:"Calibri","sans-serif"} p.dd{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif"; font-div: italic; text-align: justify}p.de{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-bottom:18.75pt;text-align:justify;background: white}span.cn{font-family:"Calibri","sans-serif";background:white}table.df{width:606.25pt;margin-left:-10.8pt;border-collapse:collapse}td.by{width:595.45pt;padding:0cm 5.4pt 0cm 5.4pt}p.dg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify}table.dh{width:18.0cm;border-collapse:collapse}td.cj{width:294.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.di{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.ch{width:194.7pt;padding:0cm 5.4pt 0cm 5.4pt} span.ci{font-family: "Calibri","sans-serif"}span.cg{font-family: "Calibri","sans-serif";color:black}p.dj{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";text-align:justify; text-autospace:ideograph-numeric ideograph-other}p.dk{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight: bold; punctuation-wrap: hanging; text-align: justify; text-autospace: ideograph-numeric ideograph-other}span.dl{color:blue;font-family:"Calibri","sans-serif"; color:windowtext;text-decoration:none}p.dm{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";margin-right:-5.4pt;text-align:justify}td.cb{width:150.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.ca{border:none;padding:0cm 0cm 0cm 0cm}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:10.0pt;font-family:"Times New Roman","serif";}td.bw{width:456.8pt;padding:0cm 5.4pt 0cm 5.4pt} p.dn{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;margin-right:-157.35pt;margin-bottom:0cm; margin-left:0cm;margin-bottom:.0001pt;text-align:justify}td.bv{border:none}span.do{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; text-decoration: none} /**/
RNS Number : 5794U
Immupharma PLC
01 April 2019
 

 

                                                                                                                                                                                1 April 2019

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

UPDATE ON NUCANT CANCER PROGRAMME

Clinical Development Collaboration with Incanthera

 

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company provides an update in relation to its discussions with Incanthera Limited ("Incanthera") on its Nucant cancer programme.

 

Background

 

On 7 September 2018, ImmuPharma announced that it had signed Heads of Terms with Incanthera, a specialist oncology company, and that it had invested £2m into Incanthera for a (circa.) 16% shareholding.

 

In addition, ImmuPharma granted Incanthera a period of exclusivity until 31 December 2018, during which it was expected to finalise the terms of a Definitive Licence Agreement for the Nucant technology. In consideration for this exclusivity period, ImmuPharma was granted warrants to subscribe for 363,637 ordinary shares in Incanthera at any time over a period of 5 years. The warrants have an exercise price of £5.50 per share, for an aggregate exercise value of £2 million.  The terms of the Definitive Licence Agreement were expected to include, inter alia, (i) Incanthera paying a licence payment to ImmuPharma of £1m, with this payment to be made via the issuance of new ordinary shares in Incanthera; (ii) that Incanthera will be responsible for all of the development costs for the Nucant programme; and (iii) all future commercialisation revenues will be shared equally between the two companies.

 

A subsequent announcement on 31 December 2018 extended the exclusivity period to 31 March 2019.

The Company and Incanthera have to date not concluded the Definitive Licence Agreement. The exclusivity period has now expired and ImmuPharma is free, should it wish, to discuss collaborations with other parties for the Nucant cancer programme.  Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for a broader collaboration.

There can be no guarantee that any agreement will be reached with Incanthera on a broader collaboration.

If an agreement is reached, the Company will make a further announcement.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.com)

+ 44 (0) 207 152 4080

Dimitri Dimitriou, Chief Executive Officer

 

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Vassil Kirtchev

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0) 203 368 8974

 

 

 

+44 (0) 203 815 8880

 

 

+44 (0) 1483 413500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCZMGFFLMGGLZM

Quick facts: ImmuPharma PLC

Price: 18.35

Market: AIM
Market Cap: £30.71 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma's Tim McCarthy details Lupuzor licensing deal with Avion...

ImmuPharma PLC's (LON:IMM) chairman Tim McCarthy caught up with Proactive's Andrew Scott to talk through the recently announced licensing deal worth almost US$100mln for Lupuzor -  its treatment for the autoimmune disease lupus. US speciality drugs group Avion Pharmaceuticals will fund...

1 week, 2 days ago